Reference number : GC-2017-Q4-01875, amendment number : , agreement type : G, recipient legal name : Weaver, Ian (Dalhousie University), recipient country : CA, recipient province : nan, recipient city : Nova Scotia|Nouvelle-Écosse, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Soricimed Biopharma, Inc. is a Sackville/Moncton, New Brunswick based company developing_x000D_
biopharmaceutical compounds based on soricidin, a paralytic protein found in the saliva of the Northern_x000D_
Short-tailed Shrew. SOR-C13, the company's lead compound, is a synthetic, 13-mer peptide whose therapeutic_x000D_
activity is based on its interaction with a calcium channel, TRPV6, whose expression is elevated in certain cell_x000D_
types (e.g. cancer cells). Also, derivatives of SOR-C13 (C-peptides) can be used as vehicles to deliver other_x000D_
drugs directly into TRPV6-bearing cells. Optimization of this drug delivery platform is hampered by the_x000D_
current lack of a significant in-house tool; a stable cell line overexpressing the TRPV6 channel. Under this_x000D_
Engage Grant, Dr. Weaver's lab will develop this cell line, allowing Soricimed to determine what properties of_x000D_
the C-peptide derivatives improve their interaction with TRPV channels and hence their ability to target and_x000D_
enter cells bearing these channels. This gained knowledge would in turn lead to expansion of the company's_x000D_
product line with new and improved therapeutic C-peptides, and novel C-peptide/drug conjugates targeting_x000D_
specific cell types. Broadening and solidifying the company's pipeline with such products will lead to_x000D_
partnerships with larger biopharma companies and expand Soricimed's drug marketability., program purpose french : Soricimed Biopharma, Inc. is a Sackville/Moncton, New Brunswick based company developing_x000D_
biopharmaceutical compounds based on soricidin, a paralytic protein found in the saliva of the Northern_x000D_
Short-tailed Shrew. SOR-C13, the company's lead compound, is a synthetic, 13-mer peptide whose therapeutic_x000D_
activity is based on its interaction with a calcium channel, TRPV6, whose expression is elevated in certain cell_x000D_
types (e.g. cancer cells). Also, derivatives of SOR-C13 (C-peptides) can be used as vehicles to deliver other_x000D_
drugs directly into TRPV6-bearing cells. Optimization of this drug delivery platform is hampered by the_x000D_
current lack of a significant in-house tool; a stable cell line overexpressing the TRPV6 channel. Under this_x000D_
Engage Grant, Dr. Weaver's lab will develop this cell line, allowing Soricimed to determine what properties of_x000D_
the C-peptide derivatives improve their interaction with TRPV channels and hence their ability to target and_x000D_
enter cells bearing these channels. This gained knowledge would in turn lead to expansion of the company's_x000D_
product line with new and improved therapeutic C-peptides, and novel C-peptide/drug conjugates targeting_x000D_
specific cell types. Broadening and solidifying the company's pipeline with such products will lead to_x000D_
partnerships with larger biopharma companies and expand Soricimed's drug marketability., agreement title english : Engineering of Stable Cell Lines Expressing TRPV Cation Channel Proteins, agreement title french : Engineering of Stable Cell Lines Expressing TRPV Cation Channel Proteins, agreement number : EGP, agreement value : 24859.0, agreement start date : 2018-03-07, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada